比较1天与3天静脉特利加压素在肝硬化食管胃静脉曲张出血患者中的疗效:一项先导性随机对照试验
这项开放标签随机对照试验纳入150例肝硬化急性食管胃静脉曲张出血患者,内镜止血后分别接受1天(n=75)或3天(n=75)特利加压素治疗,改良意向性分析纳入149例。1天组与3天组5天再出血率、5天死亡率、42天再出血率及42天死亡率均相似,但1天组不良反应显著更少(37.8% vs 56%,P=0.026)。作者认为1天特利加压素方案安全性更优,但需双盲、更大样本、多民族、多中心研究验证。
要点
- 1天与3天特利加压素组5天再出血率分别为4.1%与5.3%,差异无统计学意义(P=0.726)。
- 1天组不良反应发生率为37.8%,显著低于3天组的56%(P=0.026)。
- 42天再出血率(12.2% vs 13.3%)与42天死亡率(6.8% vs 5.3%)两组相似。
核心结论
- 作者认为,与3天特利加压素治疗相比,1天特利加压素治疗与相似的5天和42天再出血率、42天死亡率相关,且总体安全性更优。
- 作者指出这些发现需在双盲、更大样本、多民族、多中心研究及不同肝硬化阶段中验证。
研究设计与样本
- 开放标签随机对照试验,纳入150例肝硬化急性食管胃静脉曲张出血患者,随机接受1天(n=75)或3天(n=75)特利加压素治疗。
- 1天组排除1例,改良意向性分析纳入149例,两组基线特征可比。
主要发现
- 5天再出血:1天组3例(4.1%;95%CI 0.4-9.0) vs 3天组4例(5.3%;95%CI 2.0-10.0),风险差P=0.726。
- 5天死亡率:1天组1例(1.4%;95%CI 0-7.3) vs 3天组1例(1.3%;95%CI 0.2-7.0),风险差P=0.960。
- 42天再出血:1天组9例(12.2%;95%CI 7.0-20.0) vs 3天组10例(13.3%;95%CI 7.0-20.0),风险差P=0.842。
- 42天死亡率:1天组5例(6.8%;95%CI 3.0-10.0) vs 3天组4例(5.3%;95%CI 2.0-10.0),风险差P=0.704。
- 不良反应:1天组28例(37.8%) vs 3天组42例(56%),P=0.026,1天组显著更少。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出这些发现需在双盲、更大样本、多民族、多中心研究及不同肝硬化阶段中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In cirrhosis patients with acute variceal bleeding (AVB), the optimal duration of vasoconstrictor therapy after endoscopic haemostasis is unclear. AIMS: We aimed to compare efficacy of 1-day versus 3-day terlipressin therapy in cirrhosis patients with AVB post-endoscopic intervention. The primary objective was to compare rebleeding at 5 days between the two arms. Secondary objectives included rebleeding and mortality rates at 6 weeks. METHODS: In this open-label, randomised controlled trial, cirrhosis patients with AVB were randomised to either 1-day or 3-day terlipressin therapy. RESULTS: A total of 150 cirrhosis patients with AVB were recruited to receive either 1 day (n = 75) or 3 days (n = 75) of terlipressin therapy. One patient from 1-day arm was excluded. Modified intention-to-treat analysis included 149 patients. Baseline characteristics were comparable between the two groups. Rebleeding at 5 days: 3 (4.1%; 95% confidence interval [CI]: 0.4-9.0) versus 4 (5.3%; 95% CI: 2.0-10.0), risk difference (RD) p = 0.726 and 5-day mortality rates: 1 (1.4%; 95% CI: 0-7.3) versus 1 (1.3%; 95% CI: 0.2-7.0), RD p = 0.960 were similar. Rebleeding at 42 days: 9 (12.2%; 95% CI: 7.0-20.0) versus 10 (13.3%; 95% CI: 7.0-20.0), RD p = 0.842 and mortality at 42 days: 5 (6.8%; 95% CI: 3.0-10.0) versus 4 (5.3%; 95% CI: 2.0-10.0), RD p = 0.704 were also similar. Patients in the 1-day terlipressin therapy arm experienced significantly fewer adverse effects compared with those receiving 3 days of terlipressin therapy: 28 (37.8%) versus 42 (56%), p = 0.026. CONCLUSIONS: Our results suggest that 1 day of terlipressin therapy is associated with similar 5-day and 42-day rebleeding rates, 42-day mortality and an overall superior safety profile compared with 3-day of terlipressin therapy. These findings require to be validated in double-blinded, larger, multiethnic and multicentre studies across the various stages of cirrhosis (CTRI/2019/10/021771).
引用
- Vaishnav M, Biswas S, Shenoy A, et al. Comparison of 1-day versus 3-day intravenous terlipressin in cirrhosis patients with variceal bleeding: A pilot randomised controlled trial. Aliment Pharmacol Ther. 2024. PMID: 38186012. doi:10.1111/apt.17868
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。